Table 2.

Univariate analysis of DFS and PFS in 140 patients with upper urinary tract urothelial carcinoma

Variable	n	DFS		PFS
		χ2	P-value	χ2	P-value
Age (years)
<70	81	10.734	0.001	6.828	0.009
≥70	59
Sex
Male	86	0.09	0.765	0.226	0.635
Female	54
Smoking status
Yes	40	7.297	0.007	5.924	0.015
No	100
Hypertension
Yes	53	0.011	0.917	0.277	0.599
No	87
Diabetes
Yes	21	0.011	0.915	0.655	0.418
No	119
Tumor location
Left	65	2.106	0.147	0.222	0.637
Right	75
Tumor necrosis
Yes	5	1.351	0.245	0.766	0.382
No	135
Hematuresis
Yes	107	0.05	0.822	0.054	0.816
No	33
Hydronephrosis
Yes	82	0.099	0.753	0.038	0.846
No	58
Bladder cancer
Yes	12	0.595	0.441	2.27	0.132
No	128
Tumor grade
1/2	67	2.689	0.101	5.64	0.018
3	73
Pathological T stage
a-2	88	44.272	0.000	60.893	0.000
3/4	52
LVI
Yes	6	11.551	0.001	12.549	0.000
No	134
NLR
≥2.2	63	14.473	0.000	28.806	0.000
<2.2	77
PLR
≥128	47	6.7	0.01	17.071	0.000
<128	93
LMR
≥3.6	77	17.841	0.000	26.635	0.000
<3.6	63

Abbreviations: DFS, disease-free survival; LMR, lymphocyte–monocyte ratio; NLR, neutrophil–lymphocyte ratio; PFS, progression-free survival; PLR, platelet–lymphocyte ratio; LVI, lymphovascular invasion.